Otto S. Hoekstra

About

Otto S. Hoekstra is a leading researcher in the field of oncological imaging, with a primary focus on the application of prostate-specific membrane antigen (PSMA) PET/CT for the diagnosis and staging of prostate cancer. His major contributions center on the clinical validation of 18F-DCFPyL PET/CT, demonstrating its superior accuracy compared to conventional imaging for detecting lymph-node metastases and localizing primary tumors. Notably, his work on the SALT trial (106 citations) rigorously evaluated PSMA PET/CT against extended pelvic lymph-node dissection, setting a new standard for pre-surgical staging. Similarly, the DeTeCT trial (47 citations) explored the feasibility of PSMA-targeted biopsy by correlating PET findings with final histopathology from radical prostatectomy specimens. In a pioneering move, Hoekstra integrated machine learning with PET radiomics (135 citations), developing models that non-invasively stratify risk in primary prostate cancer patients. This work bridges quantitative imaging and artificial intelligence, offering a pathway toward personalized treatment decisions. With over 280 citations across his most influential papers, Hoekstra’s research has directly shaped contemporary guidelines for prostate cancer management, establishing him as a key figure in the translation of molecular imaging from bench to bedside.

Research Focus

Key Achievements

Top Papers

1. 1
   Machine learning-based analysis of [18F]DCFPyL PET radiomics for risk stratification in primary prostate cancer

   135 citations · 2020
2. 2
   Pelvic lymph-node staging with 18F-DCFPyL PET/CT prior to extended pelvic lymph-node dissection in primary prostate cancer - the SALT trial -

   106 citations · 2020
3. 3
   Detection of prostate cancer with 18F-DCFPyL PET/CT compared to final histopathology of radical prostatectomy specimens: is PSMA-targeted biopsy feasible? The DeTeCT trial

   47 citations · 2020

Key Collaborators

Contact & Links